Details Basic Details Date Sunday, August 25, 2019 Type Presentation Medical Product dabigatran edoxaban tosylate novel oral anticoagulant (NOAC) rivaroxaban warfarin Materials Characteristics of NOAC Users Aged Less Than 65 Years in the Sentinel System Additional Information Information Host 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Related Assessment(s) Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24‐28, 2019 Sentinel Drug Study: Eliquis (Apixaban), Pradaxa (Dabigatran), and Xarelto (Rivaroxaban) & Gastrointestinal Bleeding, Intracranial Hemorrhage, Major Extracranial Bleeding, and Thromboembolic Stroke Publication: Stroke and Bleeding Risks with Non-Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation Contributors Presenter(s) Marie C. Bradley, Emily C. Welch, Efe Eworuke, Rongmei Zhang, Elande Baro, David J. Graham, Mayura Shinde